资讯

Reuters7 天
US FDA approves Verastem's ovarian cancer therapy
May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's (VSTM.O), opens new tab combination therapy for patients with a rare type of ovarian cancer who have received prior ...
PMLive3 天
FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type
The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...
Pharmabiz5 天
US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS ...
US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...
Fierce Pharma6 天
Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ...
In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...
PharmExec6 天
FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS ...
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...
The Pharma Letter6 天
FDA nod for first-ever treatment for LGSOC, a rare cancer
The US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) ...
STAT6 天
FDA approves Verastem’s ovarian cancer treatment
Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...
CURE6 天
FDA Approves Avmapki Fakzynja Co-pack for KRAS Serous Ovarian Cancer
Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...